Structural and functional tuning of ZIF-8 nanoparticles via zinc salt variation and ligand ratio for enhanced drug delivery
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Metal-Organic Frameworks: Synthesis and Applications · Nanoplatforms for cancer theranostics · Crystallography and molecular interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (59)
Show source-provided references
1. Sung H, Siegel RL, Rosenberg PS, Jemal A (2024) Global cancer statistics 2024. CA Cancer J Clin 74:102–125. https://doi.org/10.3322/caac.2183410.3322/caac.21834 ↗
2. Ferlay J, Laversanne M, Ervik M et al (2023) Global cancer incidence and mortality worldwide: GLOBOCAN 2023 estimates. Int J Cancer 152:933–947
3. Chatterjee K, Zhang Q, Zhang H, Kopeček J (2024) Strategies to overcome multidrug resistance in cancer. Chem Rev 124:85–127. https://doi.org/10.1021/acs.chemrev.3c0081210.1021/acs.chemrev.3c00812 ↗
4. Zhang H, Li Y, Shi J (2023) Nanocarrier designs that rejuvenate doxorubicin. Adv Drug Deliv Rev 197:114832. https://doi.org/10.1016/j.addr.2023.11483210.1016/j.addr.2023.114832 ↗
5. Li X, Kwon N, Kim DJ, Yoon J (2024) Stimuli-responsive nanomedicine for combination chemo-immunotherapy. Biomaterials 306:122140. https://doi.org/10.1016/j.biomaterials.2023.12214010.1016/j.biomaterials.2023.122140 ↗
6. Volkova M, Cupp LB, Abramson Z (2022) Anthracycline cardiotoxicity: mechanisms and modulation. Heart Fail Rev 27:795–809. https://doi.org/10.1007/s10741-021-10119-310.1007/s10741-021-10119-3 ↗
7. Lyu Y, Chen L, Zhao R et al (2023) Organ-specific toxicities of doxorubicin and mitigation strategies. Front Pharmacol 14:1123468. https://doi.org/10.3389/fphar.2023.112346810.3389/fphar.2023.1123468 ↗
8. Zhao Y, Wang N, Huang Z (2024) Engineered nanocarriers to attenuate anthracycline toxicity. Nano Today 54:101704. https://doi.org/10.1016/j.nantod.2024.10170410.1016/j.nantod.2024.101704 ↗
9. Wang S, Li B, Chen C (2024) EPR effect 2.0: lessons from 30 years of nanomedicine. Small 20:e2307468. https://doi.org/10.1002/smll.20230746810.1002/smll.202307468 ↗
10. Guo X, Wang C, Sun J (2023) Active-targeting strategies of polymeric nanoparticles. J Control Release 360:1154–1172. https://doi.org/10.1016/j.jconrel.2023.04.03610.1016/j.jconrel.2023.04.036 ↗
11. Kim J, Lee H, Koo H (2023) Stimuli-responsive drug-delivery platforms. Acta Biomater 161:76–93. https://doi.org/10.1016/j.actbio.2023.02.04410.1016/j.actbio.2023.02.044 ↗
12. Liu Y, Luo Z, Chen Y (2023) Ph-responsive nanocarriers for tumor therapy. Coord Chem Rev 489:215040. https://doi.org/10.1016/j.ccr.2023.21504010.1016/j.ccr.2023.215040 ↗
13. Cai W, Kong X, Wuttke S (2024) MOF nanomedicine: state of the art 2024. Adv Sci 11:2307312. https://doi.org/10.1002/advs.20230731210.1002/advs.202307312 ↗
14. Rojas S, Horcajada P (2023) Metal–organic frameworks in biomedicine. Chem Soc Rev 52:1920–1950. https://doi.org/10.1039/D2CS00709J10.1039/D2CS00709J ↗
15. Huang Y, Chen Y, Sun Y (2022) Functionalised ZIF-8 for biomedical applications. ACS Appl Mater Interfaces 14:36405–36418. https://doi.org/10.1021/acsami.2c0993810.1021/acsami.2c09938 ↗
16. Wu X, Li L, Zhang F (2023) Biomedical applications of ZIF-8. Drug Discov Today 28:103659. https://doi.org/10.1016/j.drudis.2023.10409310.1016/j.drudis.2023.104093 ↗
17. Chen Y, Li S, Liu Y (2023) Recent advances of ZIF-8 in drug delivery. Nanoscale 15:6680–6694. https://doi.org/10.1039/D2NR06661F10.1039/D2NR06661F ↗
18. Liu C, Patel R, Zhang H (2023) Biodegradable MOF nanocarriers Front Chem 11:1214458. https://doi.org/10.3389/fchem.2023.121445810.3389/fchem.2023.1214458 ↗
19. Sun Y, Wu D, Li B (2024) Acid-triggered payload release from ZIF-8. J Mater Chem B 12:551–569. https://doi.org/10.1039/D3TB02263G10.1039/D3TB02263G ↗
20. Hao J, Deng H, Lin Y (2024) Engineering ZIF-8 nanoparticles for chemo-phototherapy. ACS Nano 18:404–417. https://doi.org/10.1021/acsnano.3c0655210.1021/acsnano.3c06552 ↗
21. Shen M, Wang H, Zhou J (2023) Folate-targeted DOX@ZIF-8 bioconjugates. Bioconjug Chem 34:1429–1443. https://doi.org/10.1021/acs.bioconjchem.3c0025210.1021/acs.bioconjchem.3c00252 ↗
22. Huang Z, Liu S, Chen L (2023) pH-responsive DOX@ZIF-8 for combination therapy. Mol Pharm 20:3378–3390. https://doi.org/10.1021/acs.molpharmaceut.3c0038810.1021/acs.molpharmaceut.3c00388 ↗
23. Liu Z, Zhang X, Yang P (2023) Cisplatin-loaded ZIF-8 nanoparticles: synthesis and evaluation. Int J Pharm 638:122986. https://doi.org/10.1016/j.ijpharm.2023.12298610.1016/j.ijpharm.2023.122986 ↗
24. Zhang Y, Wu Q, Fang W (2023) Paclitaxel@ZIF-8 improves antitumor efficacy. Adv Healthc Mater 12:2202403. https://doi.org/10.1002/adhm.20220240310.1002/adhm.202202403 ↗
25. Yang G, Zhou F, Zhang M (2024) Protonation-induced disassembly of ZIF-8 for controlled drug release. ACS Appl Mater Interfaces 16:12345–12356. https://doi.org/10.1021/acsami.3c1785410.1021/acsami.3c17854 ↗
26. Li B, Sun H, Huang X (2023) Low intrinsic cytotoxicity of ZIF-8 carriers. Colloids Surf B Biointerfaces 221:113014. https://doi.org/10.1016/j.colsurfb.2023.11301410.1016/j.colsurfb.2023.113014 ↗
27. Wang Y, Chen K, Luo Z (2024) Biodegradation behaviour of ZIF-8 under physiological conditions. Biomaterials 295:121973. https://doi.org/10.1016/j.biomaterials.2023.12197310.1016/j.biomaterials.2023.121973 ↗
28. Dong X, Tian C, Xu Z (2023) MOF encapsulation preserves doxorubicin integrity. Adv Mater 35:2207345. https://doi.org/10.1002/adma.20220734510.1002/adma.202207345 ↗
29. Nguyen HH, Phan HT, Le TT (2023) Degradation kinetics of BSA@ZIF-8: effect of zinc salt and ligand ratio. ACS Omega 8:27965–27978. https://doi.org/10.1021/acsomega.3c0398510.1021/acsomega.3c03985 ↗
30. Lamora VP, Chen X, Yuan D (2024) Rate of zinc-salt addition dictates ZIF-8 morphology. J Colloid Interface Sci 643:510–519. https://doi.org/10.1016/j.jcis.2024.05.04610.1016/j.jcis.2024.05.046 ↗
31. Wei Q, Pérez-Ramírez J (2024) Unified roadmap for ZIF-8 nucleation and growth. Chem Mater 36:2945–2959. https://doi.org/10.1021/acs.chemmater.3c0347710.1021/acs.chemmater.3c03477 ↗
32. Liu J, Guo R, Zhang Y (2023) Reaction parameters govern ZIF-8 integrity and degradation. J Phys Chem C 127:21554–21566. https://doi.org/10.1021/acs.jpcc.3c0561210.1021/acs.jpcc.3c05612 ↗
33. Huang L, Xiong G, Li J (2022) Metal-salt choice modulates nucleation and cellular uptake of ZIF-8. Nanoscale 14:15920–15932. https://doi.org/10.1039/D2NR03667E10.1039/D2NR03667E ↗
34. Chen T, Xiao Y, Li L (2017) Effect of zinc salts on ZIF-8 microstructure. Microporous Mesoporous Mater 245:50–58. https://doi.org/10.1016/j.micromeso.2017.04.01610.1016/j.micromeso.2017.04.016 ↗
35. Van Houten J, Barberi RC, King J, Ogata AF (2024) Improving colloidal stability of protein@ZIF-8 in buffers. Mater Adv 5:5945–5955. https://doi.org/10.1039/D4MA00377B10.1039/D4MA00377B ↗
36. Ragon F, Leclerc H, Wuttke S (2024) Synthesis method and metal source influence on ZIF-8 size. CrystEngComm 26:1905–1913. https://doi.org/10.1039/D3CE01541H10.1039/D3CE01541H ↗
37. Zhang J, Zhang G, Liu X et al (2019) Solvent effect on the synthesis and morphology of ZIF-8 crystals. J Solid State Chem 270:165–172. https://doi.org/10.1016/j.jssc.2018.11.00410.1016/j.jssc.2018.11.004 ↗
38. Cravillon J, Münzer S, Lohmeier SJ, Feldhoff A, Huber K, Wiebcke M (2011) Controlling ZIF-8 particle size and morphology by synthesis conditions. Chem Mater 23:2130–2141. https://doi.org/10.1021/cm102032n10.1021/cm102032n ↗
39. Lu G, Li S, Guo Z, Farha OK, Hauser BG, Qi X, Wang Y, Wang X, Han S, Liu X, Duchene JS, Zhang H, Zhang Q, Chen X, Ma J, Loo SCJ, Wei WD, Yang Y, Hupp JT, Huo F (2012) Imparting functionality to a metal–organic framework material by controlled nanoparticle encapsulation. Nat Chem 4:310–316. https://doi.org/10.1038/nchem.127210.1038/nchem.1272 ↗
40. Forgan RS, Sauvage JP, Stoddart JF (2012) Functionalization of metal–organic frameworks. Chem Rev 112:1128–1163. https://doi.org/10.1021/cr200010h10.1021/cr200010h ↗
41. Yu X, Dutta S, Andreo J, Wuttke S (2024) Identifying synthetic variables influencing microfluidic ZIF-8 synthesis. Commun Mater 5:210. https://doi.org/10.1038/s43246-024-00456-x10.1038/s43246-024-00456-x ↗
42. Pérez-Ramírez J, Zhang H, Horcajada P (2022) ZIF-8 drug-delivery systems: current gaps and future directions. Front Bioeng Biotechnol 10:9057214. https://doi.org/10.3389/fbioe.2022.905721410.3389/fbioe.2022.9057214 ↗
43. Pan Y, Liu Y, Zeng G, Zhao L, Lai Z (2011) Rapid synthesis of zeolitic imidazolate framework-8 (ZIF-8) nanocrystals in an aqueous system. Chem Commun 47:2071–2073. https://doi.org/10.1039/c0cc05002d10.1039/c0cc05002d ↗
44. Kaur R, Badea I, Gill RK (2017) Synthesis of nanosized ZIF-8 for drug delivery applications. J Nanosci Nanotechnol 17:4356–4364. https://doi.org/10.1166/jnn.2017.1408910.1166/jnn.2017.14089 ↗
45. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63. https://doi.org/10.1016/0022-1759(83)90303-410.1016/0022-1759(83)90303-4 ↗
46. Freshney RI (1994) Culture of Animal Cells: A Manual of Basic Technique, 3rd edn. Wiley-Liss, New York
47. Ta TD, Nguyen VH, Ta HQ (2018) Impact of zinc salts on the formation and properties of zeolitic imidazolate frameworks. Microporous Mesoporous Mater 255:7–13. https://doi.org/10.1016/j.micromeso.2017.06.02110.1016/j.micromeso.2017.06.021 ↗
48. Schejn A, Balan L, Falk V, Aranda L, Medjahdi G, Schneider R (2014) Controlling ZIF-8 nano- and microcrystal formation and size. CrystEngComm 16:4493–4500. https://doi.org/10.1039/C3CE42485E10.1039/C3CE42485E ↗
49. Li X, Zhang Y, Ding H et al (2017) Controlled synthesis of nanoscale ZIF-8 with a hierarchical structure for efficient drug delivery. ACS Appl Mater Interfaces 9:17998–18005. https://doi.org/10.1021/acsami.7b0323010.1021/acsami.7b03230 ↗
50. Park KS, Ni Z, Côté AP, Choi JY, Huang R, Uribe-Romo FJ et al (2006) Exceptional chemical and thermal stability of zeolitic imidazolate frameworks. Proc Natl Acad Sci U S A 103:10186–10191. https://doi.org/10.1073/pnas.060243910310.1073/pnas.0602439103 ↗
51. Al-Salama T (2014) Shape evolution of ZIF-8 nanocrystals: from cubes to rhombic dodecahedra. Cryst Growth Des 14:1914–1920. https://doi.org/10.1021/cg500027x10.1021/cg500027x ↗
52. Ren K, Wang Y, Liu Y (2021) Solvent-mediated doxorubicin loading on metal–organic frameworks for enhanced drug delivery performance. J Mater Chem B 9:2915–2925. https://doi.org/10.1039/D0TB02864F10.1039/D0TB02864F ↗
53. Liang K, Ricco R, Doherty CM et al (2015) Biomimetic mineralization of metal–organic frameworks as protective coatings for biomacromolecules. Nat Commun 6:7240. https://doi.org/10.1038/ncomms824010.1038/ncomms8240 ↗
54. Chouhan R, Bajpai AK (2009) Release dynamics of doxorubicin from ternary hydrogel nanocomposites: FTIR and SEM analyses. React Funct Polym 69:272–281. https://doi.org/10.1016/j.reactfunctpolym.2009.01.00810.1016/j.reactfunctpolym.2009.01.008 ↗
55. Horcajada P, Gref R, Baati T, Allan PK, Maurin G, Couvreur P et al (2012) Metal–organic frameworks in biomedicine. Chem Rev 112:1232–1268. https://doi.org/10.1021/cr200256v10.1021/cr200256v ↗
56. He C, Lu K, Lin W (2014) Nanoscale metal–organic frameworks for real-time intracellular pH sensing in live cells. J Am Chem Soc 136:12253–12256. https://doi.org/10.1021/ja507333c10.1021/ja507333c ↗
57. Liang W, Wied P, Carraro F et al (2019) Metal–organic framework-based nanocarriers for drug delivery. Adv Mater 31:1900310. https://doi.org/10.1002/adma.20190031010.1002/adma.201900310 ↗
58. Xu X, Wu H, Liu Y et al (2018) pH-sensitive ZIF-8 nanoparticles as a controlled release carrier of 5-fluorouracil. Mater Lett 219:144–147. https://doi.org/10.1016/j.matlet.2018.02.09310.1016/j.matlet.2018.02.093 ↗
59. Kaskel S (2016) The chemistry of metal-organic frameworks: synthesis, characterization, and applications. Wiley-VCH, Weinheim